|
|
||||||||
RAPID COMMUNICATION |
University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
1 University of Lübeck, Department of Internal Medicine I, 23538 Lübeck, Germany
(Requests for offprints should be addressed to M Fasshauer, Ph.-Rosenthal-Str.27, 04103 Leipzig, Germany; Email: mathias.fasshauer{at}medizin.uni-leipzig.de)
Recently, visfatin was characterized as a novel adipo-cytokine that is upregulated in obesity and exerts insulin-mimetic effects in various tissues. To clarify expression and regulation of this adipocytokine, visfatin mRNA was measured by quantitative real-time reverse transcription-polymerase chain reaction in 3T3-L1 adipocytes during adipogenesis and after treatment with various hormones known to alter insulin sensitivity. Visfatin expression was about 6-fold higher in 3T3-L1 adipocytes in vitro as compared with epididymal fat in vivo and increased during adipogenic conversion more than 3-fold. Interestingly, 100 nM dexamethasone significantly increased visfatin mRNA by almost 1.5-fold. In contrast, 500 ng/ml growth hormone (GH), 10 ng/ml tumor necrosis factor (TNF)
, and 10 µM isoproterenol downregulated visfatin expression by 45%, 36%, and 43% respectively. Insulin did not influence synthesis of this adipocytokine. The effects of dexamethasone, GH, TNF
and isoproterenol were time- and dose-dependent. Furthermore, activation of Gs-protein-coupled pathways by forskolin and cholera toxin was sufficient to significantly downregulate visfatin mRNA. Taken together, our results show a differential regulation of visfatin mRNA by insulin resistance-inducing hormones, supporting the view that this adipo-cytokine might be an interesting novel candidate linking core components of the metabolic syndrome such as obesity and insulin resistance.
This article has been cited by other articles:
![]() |
T. Luk, Z. Malam, and J. C. Marshall Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity J. Leukoc. Biol., April 1, 2008; 83(4): 804 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Dahl, A. Yndestad, M. Skjelland, E. Oie, A. Dahl, A. Michelsen, J. K. Damas, S. H. Tunheim, T. Ueland, C. Smith, et al. Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis: Possible Role in Inflammation and Plaque Destabilization Circulation, February 27, 2007; 115(8): 972 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Frydelund-Larsen, T. Akerstrom, S. Nielsen, P. Keller, C. Keller, and B. K. Pedersen Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E24 - E31. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lopez-Bermejo, B. Chico-Julia, M. Fernandez-Balsells, M. Recasens, E. Esteve, R. Casamitjana, W. Ricart, and J.-M. Fernandez-Real Serum Visfatin Increases With Progressive {beta}-Cell Deterioration. Diabetes, October 1, 2006; 55(10): 2871 - 2875. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Bailey, J C. Loredo-Osti, P. Lepage, J. Faith, J. Fontaine, K. M. Desbiens, T. J. Hudson, C. Bouchard, D. Gaudet, L. Perusse, et al. Common Polymorphisms in the Promoter of the Visfatin Gene (PBEF1) Influence Plasma Insulin Levels in a French-Canadian Population. Diabetes, October 1, 2006; 55(10): 2896 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Kralisch, U Lossner, M Bluher, R Paschke, M Stumvoll, and M Fasshauer Tissue inhibitor of metalloproteinase 1 expression and secretion are induced by {beta}-adrenergic stimulation in 3T3-L1 adipocytes. J. Endocrinol., June 1, 2006; 189(3): 665 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dotsch, W. Rascher, and U. Meissner Does visceral fat produce insulin? Eur. J. Endocrinol., October 1, 2005; 153(4): 475 - 476. [Full Text] [PDF] |
||||
![]() |
S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E586 - E590. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |